Additionally, cancer immunotherapies which inhibit immune checkpoints (ICs) such as programmed cell death protein 1/programmed cell death 1 ligand 1 (PD1/PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA4) have become landmarks in cancer treatment. The gene discussed is CTLA4; the disease is cancer.